Clinical Trial Update: A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg, the Currently Approved Dose [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and effectiveness of a 40 mg dose of Copaxone (glatiramer acetate) compared with the approved 20 mg dose in relapsing-remi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• COPAXONE (GLATIRAMER ACETATE)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Relapse-Remitting Multiple Sclerosis | Phase 2 | Status: COMPLETED